The idea of adapting cancer therapy to the specific molecular features of a tumor is changing the way we treat cancer, especially advanced cancer. Such features are discussed in a dedicated board (Molecular Tumor Board, MTB), in which experts from different fields (such as bioinformatics, molecular oncology, and molecular biology) work together with clinicians to select the best therapy for individual patients.
During the course, the participants will learn and practice various tools for analyzing and evaluating molecular aberrations. At the end of the workshop, the participants should be able to calculate targeted therapies for a patient themselves. The participants may also participate to the Molecular Tumor Board of the UCT Mainz (in German) or of Heidelberg (online, in English).
Teacher: PD Dr. Claudia Paret
Target: Clinician scientists, doctoral candidates, postdoctoral candidates
Next workshop: November 17-18, 2022, 1.00-5.00 p.m.
Maximum number of participants: 10
Technology: MS Teams
TransMed Credit Points: 1.2